Novartis AG agrees to sell 70.68% stake in Novartis India
Novartis AG has entered into an agreement to sell 1.74 crore shares, or 70.68% of Novartis India, to investors led by ChrysCapital. Novartis India later posted a 4.81% weekly gain even as quarterly profit and net sales declined.
Novartis India shares will be in focus after its promoter, Novartis AG, agreed to sell a majority stake in the company to a consortium of investors led by ChrysCapital. In a stock exchange filing, Novartis India said Novartis AG has entered into a share purchase agreement with WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners to divest 1.74 crore fully paid-up equity shares, representing 70.68% of the company’s paid-up equity share capital.
In the subsequent market period covered, Novartis India Ltd outperformed the Sensex with a 4.81% weekly gain against a 0.29% decline in the benchmark index. The stock closed at Rs.970.80 on March 30, 2026, down 0.99% from the previous close while the Sensex fell 2.29%, then rebounded 4.45% to Rs.1,014.00 on April 1 on volume of 44,678 shares, and rose 1.36% to Rs.1,027.75 on April 2 on volume of 34,894 shares.
On March 30, Novartis India Ltd was upgraded from a 'Strong Sell' to a 'Sell' rating, reflecting a cautious improvement in the company’s technical outlook despite persistent financial headwinds. The company’s quarterly profit after tax fell 36.8% and net sales declined 7.63%, while return on equity was 12.5% and the debt-to-equity ratio was negligible.
Technical indicators in the period were mixed. Weekly MACD and Bollinger Bands were described as bullish, while monthly MACD and RSI readings remained bearish, and daily moving averages were mildly bearish. The stock traded within a range of Rs.941.10 to Rs.989.90 on March 30 and was closer to its 52-week high of Rs.1,099.90.
The company’s long-term operating profit growth was 57.68% annually, while the debtors turnover ratio was 7.28 times. Domestic mutual funds held a 0.01% stake.